Laser beats brachytherapy for restenosis:
This article was originally published in Clinica
Executive Summary
Data from a European study have revealed that treating in stent restenosis with aggressive excimer laser debulking produces lower restenosis rates than brachytherapy. Laser debulking, using Spectranetics' CVX-300 excimer laser, resulted in a low binary stenosis rate of 20% and target lesion revascularisation rate of 17%, according to data published in the American Journal of Cardiology (July 1). In stent restenosis tissue is suitable for laser ablation as it is highly cellular, soft and free of calcifications, says the Colorado Springs, Colorado firm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.